Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Table 3 Current trends in human monoclonal antibody fusion proteins targeting IFNs in B cell malignancies

Targeted interferon-based therapy	Malignances under investigation	Research group/company	Clinical stage	References
Anti-CD38-IFNα	Multiple myeloma	Teva pharmaceuticals	Preclinical	Pogue et al. [60]
Anti-CD138-IFNα	Multiple myeloma	Division of Hematology and Oncology, Department of Medicine, UCLA (USA)	Preclinical	Vasuthasawat et al. [59]
Anti-CD20-IFNα	B cell NHL	Immungene (USA)	Pre-phase 1	Xuan et al. [57]
Anti-CD20-IFNα	B cell NHL	Immunomedics Inc (USA)	Preclinical	http://www.immunomedics.com
Anti-HLA-DR-IFNα	B cell lymphoma/leukemia, multiple myeloma	Immunomedics Inc (USA)	Preclinical	http://www.immunomedics.com
Anti-HER2/neu-IgG3-IFNα	B cell lymphoma	University of California (USA)	Preclinical	Huang et al. [17]

IFN interferon, NHL non-Hodgkin lymphoma, HLA-DR human leukocyte antigen DR, UCLA the University of California, Los Angeles

ISSN: 2162-3619